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control than those who had phenylalanine ≥360  µmol/L 
throughout life (n = 7), supporting the notion that phenyla-
lanine should be below the recommended upper treatment 
target of 360 µmol/L during childhood for better outcome 
in adulthood. Despite some results indicating additional 
influence of phenylalanine levels between 13 and 17 years 
of age, evidence for a continued influence of phenylala-
nine levels after childhood on adult outcomes was largely 
lacking. This may be explained by the fact that the patients 
in the present study had relatively low phenylalanine lev-
els during childhood (mean: 330  µmol/L, range: 219–
581 µmol/L) and thereafter (mean Index of Dietary Control 
at T2: 464  µmol/L, range: 276–743  µmol/L), which may 
have buffered against transitory periods of poor metabolic 
control during adolescence and early adulthood.
Abstract Cognitive and mental health problems in indi-
viduals with the inherited metabolic disorder phenylke-
tonuria (PKU) have often been associated with metabolic 
control and its history. For the present study executive 
functioning (EF) was assessed in 21 PKU patients during 
childhood (T1, mean age 10.4  years, SD = 2.0) and again 
in adulthood (T2, mean age 25.8 years, SD = 2.3). At T2 
additional assessments of EF in daily life and mental health 
were performed. Childhood (i.e. 0–12 years) blood pheny-
lalanine was significantly related to cognitive flexibility, 
executive motor control, EF in daily life and mental health 
in adulthood (i.e. at T2). Patients with a greater increase in 
phenylalanine levels after the age of 12 performed more 
poorly on EF-tasks at T2. Group-based analyses showed 
that patients with phenylalanine <360  µmol/L in child-
hood and phenylalanine ≥360 µmol/L from age 13 onwards 
(n = 11) had better cognitive flexibility and executive motor 
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Introduction
Notwithstanding the prevention of intellectual disability 
by decreasing blood phenylalanine (Phe) concentrations, 
the neurocognitive and psychosocial outcomes of patients 
with phenylketonuria (PKU; OMIM 212600) are on aver-
age still below the level of their healthy counterparts. PKU 
is a rare inborn error of metabolism, with a mean preva-
lence of 1:10,000, that is characterized by deficient hepatic 
enzyme phenylalanine hydroxylase (PAH) activity. PAH 
normally helps to convert Phe into tyrosine (Tyr), which is 
the precursor to l-dopa and consequently dopamine (Blau 
et  al. 2010; van Spronsen et  al. 2017). Untreated PKU 
patients show high blood Phe levels and low to normal Tyr 
levels. High blood Phe levels facilitate the blood–brain bar-
rier exchange of Phe at the expense of other large neutral 
amino acids into the brain including Tyr and tryptophan. 
Therefore, high blood Phe results in high brain levels of 
Phe that may affect white matter (Dyer 1999) and reduced 
brain availability of the precursors Tyr and tryptophan for 
the neurotransmitter synthesis of dopamine and serotonin, 
respectively. Clinically, untreated PKU is characterized by 
severe intellectual disability, neurological problems, motor 
deficits, and behavioural problems (Blau et al. 2010; DeRo-
che and Welsh 2008; Jahja et al. 2016; Smith and Knowles 
2000). Treatment, through a Phe-restricted diet plus amino 
acid supplements, tetrahydrobiopterin  (BH4, being a phar-
macological chaperone protein of PAH) supplementation, 
or both, reduces blood Phe levels, which results in lower 
Phe levels and probably higher levels of neurotransmitter 
precursors such as Tyr and tryptophan (Blau et  al. 2010; 
van Vliet et al. 2015, 2016). When started early after birth, 
treatment with dietary Phe restriction prevents intellectual 
disability, but, compared to healthy controls, PKU patients 
generally still have lower IQs and perform more poorly in 
several cognitive domains (Albrecht et al. 2009; Huijbregts 
et al. 2002a, c; Jahja et al. 2014; Moyle et al. 2007; Smith 
and Knowles 2000; Waisbren et  al. 2007). The most fre-
quently observed cognitive deficits in treated PKU are in 
executive functions (EFs), i.e. ‘higher-order cognitive abili-
ties that control and coordinate behaviour and constitute 
the driving force of goal-directed behaviour’ (Christ et al. 
2010; Huijbregts et  al. 2002c, 2003; Moyle et  al. 2007). 
Both cognitive impairment in treated PKU (Antenor-
Dorsey et  al. 2013; Blau et  al. 2010; Huijbregts et  al. 
2002c) and internalizing mental health problems, such as 
anxiety, depression and mood swings (Anjema et al. 2011; 
Arnold et al. 1998; Cappelletti et al. 2013; Jahja et al. 2013; 
Smith and Knowles 2000; Weglage et al. 2000) have repeat-
edly been associated with concurrent and historical blood 
Phe levels. However, questions remain regarding long-term 
consequences of elevated Phe in various periods of life on 
cognitive functioning in adults with PKU.
The key statements of the first European guidelines on 
PKU clearly show the lack of valuable data on the relation 
between outcome and metabolic control from adolescence 
onwards (van Spronsen et al. 2017). While there are some 
studies relating adult outcomes to history of metabolic con-
trol, and other studies indicating the existence of certain 
sensitive periods for elevated Phe with respect to cogni-
tive development (Huijbregts et  al. 2002b), none of these 
provide complete and conclusive evidence. Studies with 
repeated measurements are very scarce. One longitudinal 
study reported on neurocognitive functioning of 57 adult 
patients aged 19–41  years who were re-examined after a 
5-year interval (Weglage et al. 2013). Patients had a lower 
IQ than controls, but psychomotor function and sustained 
attention were not different between PKU patients and con-
trols at either time point. The authors further distinguished 
between participants younger and older than 32 years old: 
older patients had slower information processing than con-
trols at both time points. Group differences did not change 
during the 5-year interval. High blood Phe levels in child-
hood and adolescence were related to poorer IQ, informa-
tion processing and attention in adulthood. A limitation of 
this study of Weglage et  al. (2013) was that both assess-
ments took place during adulthood, so cognitive develop-
ment could not be mapped from childhood onwards. A 
second longitudinal study assessed 14 PKU patients in 
childhood and early adulthood. Patients were 8–14 years at 
time point 1 and 22–28  years at time point 2. That study 
showed that differences in neuropsychological outcome 
between patients and controls became smaller throughout 
adolescence and adulthood, but did not disappear (Nardec-
chia et al. 2015). Regarding lifetime Phe, specifically those 
with Phe between 501 and 600  µmol/L (n = 3) performed 
worse than those with lifetime Phe below 500  µmol/L 
(n = 4). These authors also differentiated between patients 
with Phe below or above 600  µmol/L during the inter-
val between the two time points: those with Phe above 
600  µmol/L (n = 7) during the interval had poorer cogni-
tive outcome as adults compared to controls (n = 14). This 
study provided evidence for an influence of adolescent or 
‘second decade of life’ metabolic control on adult cognitive 
outcomes. A limitation of this study was that the authors 
could not control optimally for childhood Phe levels in 
their statistical analyses, as Phe levels were only included 
for the first 4 years of life, whereas critical stages of EF-
development occur later in childhood as well (Huijbregts 
et al. 2002b). So there is no strong evidence yet that ado-
lescent or adult Phe levels truly influence adult outcome: it 
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is still possible that childhood Phe levels, which are often 
related to Phe levels later in life, most strongly determine 
adult outcome.
The present study aimed to examine mental health, and 
development of executive functioning and executive motor 
control of PKU patients from childhood into adulthood 
in relation to historic metabolic control, distinguishing 
between different developmental stages and using different 
methodological approaches, compared to previous studies.
Methods
Participants
This study is part of the Dutch longitudinal multicentre 
PKU-COBESO study. Between February 1997 and October 
1998, executive functioning and executive motor control 
were assessed in 67 children with PKU, aged 7–14  years 
(Huijbregts et  al. 2002c). Patients that could be reached 
and who were willing to participate a second time were fol-
lowed up between February 2012 and May 2015, at which 
point all of them were adults. At time point 1 (T1) and time 
point 2 (T2) identical tasks were performed, with additional 
tasks and questionnaires at T2 (Jahja et al. 2013). Patients 
were recruited through six Dutch university medical cen-
tres and on both occasions assessed in their treatment cen-
tre by the research staff. All patients were diagnosed by 
neonatal screening, which has been introduced in the Neth-
erlands in September 1974, and treated early after birth. 
At both time points, T1 and T2, blood samples were taken 
on the day of neuropsychological testing in order to obtain 
concurrent Phe levels (conPhe). Historical Phe levels were 
collected from physicians’ databases. Indices of dietary 
control (IDC) were calculated as the mean of all half-year 
median Phe levels until the day of testing. Thus, IDC1 was 
computed from birth until the day of testing at T1, and 
IDC2 (i.e. lifetime Phe) represented Phe levels from birth 
until the day of testing at T2. To create a difference score 
between both time points, i.e. to determine the increase in 
Phe between the two assessments, IDC1 was subtracted 
from IDC2 (i.e. IDC difference score). Mean of half-year 
median Phe levels between 0 and 12 years, between 13 and 
17, and ≥18 years were also calculated.
Furthermore, based on the question whether differ-
ent upper target Phe levels should be maintained dur-
ing childhood (0–12  years) and thereafter, and the 
most frequently recommended upper target Phe level 
of 360  μmol/L, patients were divided into groups: Phe 
<360 μmol/L in childhood and Phe <360 μmol/L from age 
13 (‘low–low’ group); low Phe in childhood and high Phe 
≥360  μmol/L from age 13 (‘low–high’ group); and high 
Phe ≥360 μmol/L in childhood and high Phe from age 13 
(‘high–high’ group).
Measures
The overall multicentre study (PKU-COBESO, Jahja et al. 
2013) addressed cognitive, behavioural and social sequelae 
of early and continuously treated PKU patients in relation 
to history of metabolic control. A standardized testing pro-
tocol was used for each participant and took approximately 
2.5 h to complete including breaks (Jahja et al. 2013). The 
following three computerized tasks of the Amsterdam Neu-
ropsychological Tasks (ANT; De Sonneville 2014) were 
used to assess executive functioning and executive motor 
control on two different occasions, i.e. at T1 and T2.
In the Flanker (FL) interference task, which measures 
inhibitory control but more specifically interference sup-
pression, stimuli consist of squares divided up into nine 
smaller squares. Participants must respond to the colour of 
the central smaller square, while ignoring the surrounding 
eight smaller squares (i.e. the flanker stimuli). When the 
central stimulus is blue, participants have to press the left 
mouse button; when the central stimulus is yellow, they 
have to press the right mouse button. In part 1 the flanker 
stimuli had a neutral colour (20 trials) or the same colour 
(20 trials, i.e. the compatible condition) as the central stim-
ulus, while in part 2 the flankers had the same (40 trials, 
compatible condition) or the interfering (40 trials, incom-
patible condition) colour. The interfering colour meant to 
elicit a response with the other hand if it would have been 
the central stimulus colour (Huijbregts et  al. 2002c). The 
differences in error percentage and reaction time (RT) 
between compatible and incompatible flanker stimuli in 
part 2 of the task were used to measure inhibitory control/
interference suppression.
The shifting attentional set-visual (SSV) task measures 
inhibitory control but more specifically inhibition of prepo-
tent responding, and cognitive flexibility. On the screen a 
horizontal bar consisting of ten squares is presented. In task 
part 1 (40 trials, compatible condition), participants follow 
a green block which randomly moves across the bar to left 
or to right: movements to the left require left mouse but-
ton presses and movements to the right require right mouse 
button presses. In part 2 (40 trials, incompatible condi-
tion), the randomly moving block is red and a response 
is required opposite to the direction of the movement, i.e. 
movements to the left require right mouse button presses 
and vice versa. In part 3 (80 trials), the block changed 
randomly into green or red after each movement and par-
ticipants switch between the rules of task parts 1 and 2 
(i.e. compatible and incompatible responding) depending 
on the colour of the block after each random movement 
(Huijbregts et  al. 2002a). This task requires inhibition of 
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prepotent responding, when in task part 2 a switch has to 
be made from the automatic (compatible) response mode 
in task part 1 to the incompatible response mode, and it 
requires cognitive flexibility, when in task part 3, one has 
to switch between the two active response modes based on 
the cue provided by the stimulus. The differences in error 
percentages and RT between part 1 and 2 represented inhi-
bition of prepotent responding and the differences between 
part 1 and 3 represented cognitive flexibility.
Executive motor control was measured with the pursuit 
(PU) task. Participants had to follow an asterisk, which ran-
domly moved across the screen, by placing the mouse cur-
sor as closely as possible on top of the asterisk for 2 min, 
first with their non-dominant hand, then with their domi-
nant hand (Huijbregts et  al. 2003). Mean deviation from 
the moving target (i.e. accuracy of movement), and stand-
ard deviation of the trajectory that was followed (stability 
of movement) were used in analyses. A greater deviation 
or standard deviation indicated poorer executive motor 
control.
At T2, general/demographic information was collected 
and two questionnaires were administered. First, the Behav-
ior Rating Inventory of Executive Function-Adult version 
(BRIEF-A) was used to measure executive functioning in 
daily life of adults (Roth et  al. 2005). The questionnaire 
consists of 75 questions, assessing nine subdomains of 
executive functioning: Inhibit, Shift (Cognitive Flexibil-
ity), Emotional Control, Self-Regulation, Initiate, Working 
Memory, Plan/Organize, Organization of Materials, and 
Monitor. The subdomains Inhibit, Shift, Emotional Con-
trol and Self-Regulation together represent the Behavioral 
Regulation Index (BRI). Furthermore, the combined scores 
of the other five subdomains represent the MetaCognition 
Index (MCI). The Global Executive Composite (GEC) is 
the total score of all subdomains and represents the overall 
executive functioning in daily life. Continuous T-scores of 
the BRI, MI and GEC were used in statistical analyses. For 
descriptive purposes the following distinctions were used: 
participants have normal EFs when T-scores are below 50. 
A T-score between 50 and 65 is considered increased or 
borderline, and a T-score above 65 indicates clinical sig-
nificance (i.e. in the clinical range).
Second, the Adult Self-Report (ASR) of the Achenbach 
System of Empirically Based Assessment (Achenbach and 
Rescorla 2003) measured mental health problems. It is a 
norm-referenced questionnaire consisting of 102 items with 
3-point rating scales suitable for adults. Six DSM-IV-ori-
ented scales are provided: Depressive problems, Anxiety 
problems, Somatic problems, Avoidant Personality prob-
lems, Attention Deficit/Hyperactivity problems, and Anti-
social Personality problems. Next to these subscales, the 
overall internalizing, externalizing and total problem score 
were also used. For the three overall scales, a score below 
60 is considered normal, scores between 60 and 64 are in 
the borderline range, and scores above 64 are in the clini-
cal range. Thus, higher scores represent more mental health 
problems.
Statistical Analyses
IBM SPSS Statistics 22nd version was used for statistical 
analyses. Associations between executive functioning and 
executive motor control at T1 and T2, and mental health 
at T2 on the one hand and several indicators of metabolic 
control on the other (i.e. conPhe at T2, IDC1, IDC2, IDC 
difference score, Phe 0–12, 13–17 and ≥18  years) were 
investigated using one-tailed Pearson correlations and par-
tial correlations to control for Phe 0–12  years. Repeated 
measures analyses of variance were used to compare the 
‘low–high’ groups at T1 and T2 on performance of the 
ANT-tasks measuring executive functioning and executive 
motor control. Z-scores of the EF measures at T1 and T2, 
calculated using age-appropriate performance scores from 
healthy controls in the PKU-COBESO study as norm ref-
erence, were used as dependent variables, where a low or 
negative Z-score indicated a better performance. Independ-
ent samples T-tests were conducted for comparisons of the 
‘low–high’ groups on BRIEF and ASR scores at T2.
Results
Metabolic Outcome
Twenty-one patients (31% of the original cohort; 6 male, 15 
female) completed a neuropsychological assessment at two 
time points. The remaining 69% of the original cohort was 
lost to follow up. Patients were not under treatment any-
more and/or were out of sight from physicians (n = 40) or 
were not willing to participate (n = 6), usually due to time 
constraints. IDC at T1 (t(62) = 1.1, p = 0.29) and the pre-
treatment Phe (t(64) = 0.4, p = 0.72) did not significantly 
differ between the 21 versus 46 patients, but conPhe at T1 
was higher for the 69% that was lost (t(49) = 2.0, p = 0.027). 
However, data regarding executive functioning was gath-
ered for both groups at T1. The two groups did not differ 
on inhibitory control (FL and SSV), cognitive flexibility 
(SSV) and executive motor control (PU), indicating that the 
two groups had similar executive functioning at T1.
For those 21 patients who participated at T2, mean 
age at T1 was 10.4  years (SD = 2.0) and 25.8  years 
(SD = 2.3) at T2 (see Table  1 for descriptive statistics). 
According to the traditional classification for biochemi-
cal subtypes within the hyperphenylalaninemias (Blau 
et al. 2011), four patients were classified as having hyper-
phenylalaninemia (HPA, i.e. a pre-treatment Phe level 
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below 600  μmol/L), eight as mild PKU (pre-treatment 
Phe between 600 and 1200  μmol/L) and nine had clas-
sical PKU (pre-treatment Phe ≥1200  μmol/L). Mean 
conPhe at T1 was 346  μmol/L (SD = 204) while at T2 
this was 719  μmol/L (SD = 351). Mean IDC at T1 was 
312  μmol/L (SD = 96) and IDC at T2 was 464  μmol/L 
(SD = 138). Phe levels between 0 and 12 years, between 
13 and 17 and ≥18 years are reported in Table 1. Correla-
tions between Phe variables are displayed in Table 2. Phe 
concentrations significantly increased with age, as shown 
with repeated measures including Phe 0–12, 13–17 and 
≥18  years (Wilks’Λ = 0.35, F(2,19) = 17.30, p < 0.001, 
η²p = 0.65). Within T1 and within T2, age did not sig-
nificantly correlate with Phe. At T1,  BH4 was not yet 
Table 1  Descriptive statistics PKU, and ‘low–high’ groups
BH4 tetrahydrobiopterin, IDC index of dietary control, PKU phenotype based on diagnostic Phe measurement, HPA hyperphenylalaninemia, Phe 
120–600 µmol/L, mild PKU Phe 600–1200 µmol/L, classical PKU Phe >1200 µmol/L
a The low–low group was excluded from statistical analyses because the sample size was too small
PKU = 21 Low–low = 3a Low–high = 11 High–high = 7
Mean age T1 ± SD (range) 10.5 ± 2.0 (6.9–13.7) 11.0 ± 2.3 (9.3–13.6) 10.7 ± 2.1 (6.9–13.7) 9.9 ± 1.7 (7.0–12.4)
Mean age T2 ± SD (range) 25.8 ± 2.3 (21.0–30.5) 26.6 ± 2.5 (23.9–28.7) 25.7 ± 2.8 (21.0–30.5) 25.7 ± 1.7 (23.0–28.8)
Gender (male:female) 6:15 0:3 5:6 1:6
Socio-economic status: income 7 Above average Average 5 Above average 2 Above average
Socio-economic status: education 14 Higher education 3 Higher education 7 Higher education 4 Higher education
IQ 102 ± 13 (71–120) 103 ± 14 (88–115) 103 ± 9 (92–120) 101 ± 18 (71–120)
Diagnostic Phe measurement 1300 ± 925 (120–3151) 205 ± 107 (120–325) 1252 ± 805 (450–3053) 1844 ± 904 (750–3151)
Biochemical PKU phenotype 4 HPA; 8 mild PKU; 9 
classical PKU
3 HPA 1 HPA; 6 mild PKU; 4 
classical PKU
2 mild PKU; 5 classical PKU
BH4 responsive 5 BH4 responsive 2 BH4 responsive 2 BH4 responsive 1 BH4 responsive
Concurrent Phe T1 ± SD (range) 346 ± 204 (30–860) 308 (2 missing) 257 ± 157 (30–475) 491 ± 211 (245–860)
IDC T1 ± SD (range) 315 ± 92 (192–548) 326 ± 53 (294–388) 252 ± 42 (192–327) 409 ± 84 (320–548)
Concurrent Phe T2 ± SD (range) 719 ± 351 (259–1550) 357 ± 87 (259–427) 807 ± 403 (336–1550) 735 ± 241 (345–1000)
IDC T2 ± SD (range) 464 ± 138 (276–743) 291 ± 15 (276–306) 424 ± 79 (322–547) 602 ± 112 (446–743)
IDC difference score (IDC2 minus 
IDC1)
149 ± 120 (−82–330) −35 ± −41 (−82 to −6) 172 ± 93 (52–322) 194 ± 112 (−6–330)
Phe 0–12 years ± SD (range) 330 ± 91 (219–581) 308 ± 35 (286–348) 270 ± 40 (219–331) 434 ± 71 (380–581)
Phe 13–17 years ± SD (range) 533 ± 246 (267–1069) 293 ± 30 (268–326) 475 ± 172 (272–764) 728 ± 269 (267–1069)
Phe >18 years ± SD (range) 651 ± 258 (226–1105) 253 ± 23 (226–267) 658 ± 202 (465–1068) 809 ± 211 (528–1105)
Table 2  Pearson correlations between indicators of metabolic control
p < 0.05 values are indicated in bold
IDC index of dietary control, T1 time point 1 in childhood, T2 time point 2 in adulthood
*p < 0.05 **p < 0.01 ***p < 0.001,+p < 0.10 (1-tailed)
Concur-
rent Phe 
at T1
IDC at T1 Concurrent Phe 
at T2
IDC at T2 IDC difference 
score
Phe 0–12 years Phe 13–17 years Phe ≥18years
Concurrent Phe 
at T1
1.000
IDC at T1 0.543** 1.000
Concurrent Phe 
at T2
0.221 −0.117 1.000
IDC at T2 0.529** 0.520** 0.570** 1.000
IDC difference 
score
0.170 −0.174 0.747*** 0.751*** 1.000
Phe 0–12 years 0.553** 0.933*** 0.041 0.693*** 0.078 1.000
Phe 13–17 years 0.387+ 0.234 0.488* 0.877*** 0.830*** 0.466* 1.000
Phe ≥18 years 0.385+ 0.170 0.778*** 0.876*** 0.879*** 0.328+ 0.754*** 1.000
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prescribed in the Netherlands. At T2, five patients used 
 BH4 doses up to 20 mg/kg with a max of 1400 mg/day.
Regarding the ‘low–high’ groups, three patients were 
allocated to the ‘low–low’ group (mean Phe <360 μmol/L 
when 0–12  years and from age 13 onwards), 11 patients 
were in the ‘low–high’ group (Phe <360 μmol/L until age 
12 and ≥360 μmol/L from age 13) and seven patients were 
in the ‘high–high’ group (Phe ≥360  μmol/L in childhood 
and onwards). None of the patients had high values as a 
child and low values as an adult. Descriptive statistics and 
metabolic measurements for these groups are displayed in 
Table  1. Because the first group was too small, only the 
‘low–high’ and ‘high-high’ groups were included in group-
based statistical analyses. The ‘low–high’ group consisted 
of one patient with hyperphenylalaninemia, six patients 
with mild PKU and four patients with classical PKU, while 
the ‘high-high’ group included two mild PKU patients and 
five patients with classical PKU. The pre-treatment Phe 
concentration (t(16)=  −1.5, p = 0.17) and the PKU clas-
sification (χ2 = 2.3, p = 0.31) did not differ between the 
two groups. The socio-economic status, i.e. education and 
yearly income, of these two groups was similar, respec-
tively χ2 = 3.1, p = 0.37 and χ2 = 1.7, p = 0.89.
Participant Characteristics: Relationships, Education, 
Occupation, Income
Sixteen out of 21 patients (76%) had a long-term, romantic 
relationship, 13 have had two or more long-term, roman-
tic relationships in the past. All patients completed high 
school. Eight patients (38%) followed or completed higher 
vocational education and six patients (29%) completed 
higher education (bachelor’s or master’s degree), which is 
comparable to the healthy Dutch population, according to 
the Dutch Central Bureau for Statistics (CBS 2016a). All 
patients had an occupation at T2, working 12–40 h/week. 
Seven patients (33%) had a higher than average income and 
12 out of 21 (57%) were house owners of private property, 
similar to the Dutch population (CBS 2016b).
Associations Between Metabolic Control, Executive 
Functioning and Mental Health
Regarding inhibitory control/interference suppression (FL-
task), partial correlations (controlling for Phe 0–12 years) 
showed that Phe 13–17 years, the IDC difference score and 
IDC2 were significantly associated with percentage errors 
at T2 (see Table 3 for associations between Phe and ANT-
tasks). The positive correlation between the IDC differ-
ence score and error percentage indicated that with a larger 
increase in Phe between childhood and adulthood, poorer 
performance was observed at T2.
Inhibition of prepotent responding (SSV-task) was not 
associated with any of the Phe indices. When measuring 
cognitive flexibility, the percentage of errors at T2 was sig-
nificantly correlated with Phe 13–17  years while the cor-
relation with the IDC difference score just failed to reach 
significance after controlling for Phe 0–12 years. RT at T2 
was associated with IDC1 and with Phe 0–12 years.
Regarding executive motor control (PU-task), IDC1 and 
Phe 0–12 years were significantly related to accuracy and 
stability of executive motor control at T2. These correla-
tions indicated that high Phe in childhood were related to 
poorer executive motor control in adulthood.
The Behavioral Regulation Index (BRI) of the BRIEF-
A which was only measured at T2, was significantly asso-
ciated with IDC1, Phe 0–12 years and IDC2 (see Table 4 
for correlations between Phe and questionnaires). When 
controlling for Phe 0–12 years, the correlation with IDC2 
became non-significant. The Global Executive Composite 
(GEC) was also related to Phe 0–12  years. These results 
demonstrate that childhood Phe is important for executive 
functioning in daily adult life.
With respect to mental health at T2, Depressive prob-
lems were related to Phe 0–12 years and to IDC2. Somatic 
problems had a significant relation with IDC1, Phe 
Table 3  Partial correlations (Pearson, 1-tailed) between Phe and 
ANT
p < 0.05 values are indicated in bold
Note only significant correlations and (non-significant) trends shown
IDC index of dietary control, T1 time point 1 in childhood, T2 time 
point 2 in adulthood
r p
Flanker—inhibitory control/interference suppression
 % errors T2
  Phe 13–17 years 0.578 0.004
  IDC difference 0.533 0.008
  IDC T2 0.436 0.027
Shifting attentional set-visual—cognitive flexibility
 % errors T2
  IDC difference 0.393 0.053
  Phe 13–17 years 0.426 0.039
  IDC T2 0.354 0.075
 Reaction time T2
  IDC T1 0.446 0.028
  Phe 0–12 years 0.429 0.033
Pursuit—executive motor control
 Mean deviation T2
  IDC T1 0.490 0.012
  Phe 0–12 years 0.404 0.035
 Standard deviation T2
  IDC T1 0.550 0.005
  Phe 0–12 years 0.515 0.008
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0–12  years and IDC2. IDC1 and Phe 0–12  years were 
associated with Attention Deficit/Hyperactivity problems. 
Antisocial Personality problems were related to IDC1, Phe 
0–12 years, Phe ≥18 years and IDC2. Overall internalizing 
problems were associated with IDC1 and Phe 0–12 years. 
The externalizing problem scale was related to IDC1, Phe 
0–12 years and IDC2. However, when controlling for Phe 
0–12  years, the correlations with Phe indices after child-
hood became non-significant. Finally, the overall total 
problem scale was again associated with IDC1 and Phe 
0–12 years. The IDC difference score was not significantly 
related to the ASR scores.
Multiple Testing
Regarding the neuropsychological test outcomes, correc-
tion for multiple testing (seven IDCs times eight outcome 
measures) would result in non-significant correlations only, 
as a p value of 0.0009 would be the criterion. We opted 
for calculating all these correlations as the different IDCs 
may provide (subtly) different information. Still, the IDCs 
were often strongly correlated (see Table 2). If one would 
retain only IDC at T1 and the IDC difference score, as they 
represent childhood Phe and Phe-change thereafter, and 
therefore seem the most meaningful indices, no significant 
correlations are retained either, as a p-value of 0.003 would 
be the criterion. Some could be retained by reducing the 
number of outcome measures, e.g. one per task. However, 
there is no evidence to support one should choose either 
RT, error rate, or stability of performance as main outcome 
measures of the tasks.
Questionnaire data showed stronger correlations with 
IDCs, with IDC1 and Phe0–12 correlations with the BRI 
of the BRIEF almost remaining significant after apply-
ing p-level corrections with a factor 4, i.e. two indices of 
metabolic control (i.e. IDC1 and IDC difference score or 
Phe 0–12 and Phe >12), and two outcome measures (MCI 
and BRI indices). A number of results obtained on the 
ASR actually did remain significant after applying correc-
tions with a factor 12 (i.e. two IDCs, six ASR-dimensions): 
somatic problems, attention deficit/hyperactivity problems, 
or 4 (i.e. two IDCs, two ASR-dimensions): internalizing 
and externalizing problems. The pattern of correlations 
indicated that especially those with IDC1 or Phe 0–12 were 
robust (Table  4). Further group comparisons were made 
(see below) in order to link results to upper target Phe lev-
els (for different age periods) according to current treat-
ment guidelines, and to gain more insight into development 
of cognition and mental health in PKU patients relative to 
healthy controls.
Comparison ‘Low–High’ and ‘High–High’ Groups
For inhibitory control/interference suppression (FL-task), 
repeated measures analyses of variance did not show sig-
nificant effects for time or group. Also, there was no inter-
action effect. On the SSV-task, there were no significant 
effects for inhibition of prepotent responding. Concern-
ing cognitive flexibility, the ‘low–high’ group was sig-
nificantly faster than the ‘high-high’ group at both time 
points (F(1,15) = 8.0, p = 0.013, n2p = 0.349) (see Fig.  1). 
Although descriptive statistics showed better Z-scores on 
Table 4  Partial correlations (Pearson, 1-tailed) between Phe and behavior ratings
p < 0.05 values are indicated in bold
IDC index of dietary control, T1 time point 1 in childhood, T2 time point 2 in adulthood, BRIEF-A behavior rating inventory of executive func-
tion-adult version, ASR adult self-report
IDC T1 IDC T2 Phe 0–12 years Phe 13–17 years Phe ≥18 years
r p r p r p r p r p
BRIEF-A
 Behavioural regulation index 0.454 0.025 0.415 0.039 0.501 0.014 0.173 0.239 0.288 0.116
 Global executive composite 0.329 0.084 0.361 0.064 0.397 0.046 0.233 0.168 0.264 0.138
ASR
 Depressive problems 0.346 0.073 0.402 0.044 0.456 0.025 0.322 0.090 0.266 0.135
 Anxiety problems 0.255 0.146 0.213 0.191 0.289 0.115 0.151 0.268 0.076 0.378
 Somatic problems 0.609 0.003 0.451 0.026 0.721 0.000 0.247 0.153 0.226 0.177
 Avoidant personality problems 0.383 0.053 −0.038 0.439 0.349 0.072 −0.230 0.172 −0.134 0.292
 Attention deficit/hyperactivity problems 0.567 0.006 0.351 0.070 0.572 0.005 0.169 0.244 0.211 0.193
 Antisocial personality problems 0.545 0.008 0.488 0.017 0.496 0.015 0.182 0.277 0.398 0.046
 Internalizing problems 0.512 0.012 0.130 0.298 0.568 0.006 0.007 0.488 −0.096 0.347
 Externalizing problems 0.586 0.004 0.538 0.009 0.619 0.002 0.348 0.072 0.368 0.060
 Total score 0.524 0.011 0.342 0.074 0.593 0.004 0.174 0.238 0.162 0.254
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cognitive flexibility for all patients at T2 compared to the 
age-appropriate norm, time and interaction effects were 
not significant. For executive motor control (PU-task) there 
was a significant effect for time. All participants improved 
over time compared to the age-appropriate norm: they had 
a more accurate (F(1,16) = 5.5, p = 0.033, n2p = 0.255) and 
stable (F(1,16) = 4.5, p = 0.050, n2p = 0.219) executive 
motor control at T2. Also the group effect was significant 
for stability of movement: the ‘low–high’ group had a more 
stable executive motor control than the ‘high–high’ group 
(F(1,16) = 5.6, p = 0.031, n2p = 0.259) (see Fig. 2).
Regarding the BRIEF scales on executive functioning in 
daily life, there were no statistically significant differences 
between the ‘low–high’ (n = 11) and ‘high–high’ (n = 7) 
groups. Finally, with respect to mental health as measured 
by the ASR scales, the ‘high-high’ group reported signifi-
cantly more Somatic problems than the ‘low–high’ group 
(t(14) = −3.8, p = 0.002). When examining the descriptive 
statistics, two patients from the ‘low–high’ group (18%), 
scored in the borderline range of the internalizing scale and 
had a lifetime Phe of 420 and 514 µmol/L respectively. Two 
patients (29%) from the ‘high-high’ group were in the clini-
cal range with lifetime Phe of 446 and 678 µmol/L. The lat-
ter patient with the highest Phe also scored in the clinical 
range of the externalizing and overall total problem scale. 
This patient also scored in the clinical range of the BRIEF. 
The patients in the normal range had similar lifetime and 
childhood Phe as those in the borderline and clinical range.
Discussion
The present study provided evidence for long-term effects 
of elevated childhood Phe on cognitive functioning and 
mental health during adulthood, although specifically for 
a number of cognitive indices more recent Phe levels, par-
ticularly Phe level between 13 and 17 years of age, were 
also associated with outcome, even after controlling for 
childhood Phe. Results confirmed that Phe levels increase 
with age. Phe levels increased in adolescence and were 
the highest in adulthood. This is consistent with results of 
previous studies (e.g. Walter et al. 2002; Walter and White 
2004) and may be due to the fact that recommended treat-
ment targets are higher in adolescence and adulthood com-
pared to childhood (Blau et al. 2010; Weglage et al. 2013). 
A larger increase from childhood to adult Phe levels was 
associated with poorer inhibitory control/interference sup-
pression and cognitive flexibility, as measured with the 
ANT, during adulthood.
Examining the changes in outcome between child-
hood and adulthood showed that executive motor func-
tion improved over time for PKU patients relative to the 
norm reference of healthy controls, whereas this was not 
observed for inhibitory control and cognitive flexibility. 
These last results are in line with findings from the study of 
Weglage et al. (2013), who concluded that in 5 years’ time 
cognitive performance of adult patients remained stable, 
despite an increase in Phe levels. The present study showed 
that such stability of relative deficits apparently extends 
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Fig. 1  Reaction time of cognitive flexibility. Group effect was sig-
nificant: at both time points the low–high group performed faster than 
the high–high group
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Fig. 2  Executive motor control: accuracy and stability of movement. 
Time effect was significant for accuracy and stability: all participants 
improved over time. Group effect was significant for stability only: 
the low–high group had a more stable executive motor control than 
the high–high group
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over a period of 10–15  years. In line with findings from 
Nardecchia et al. (2015) we showed a significant improve-
ment relative to healthy controls in executive motor control 
between childhood/adolescence and adulthood. Nardecchia 
et al. (2015) reported relative improvements for other cog-
nitive domains as well, incorporating a period between test 
occasions that was almost as long as ours, but in a sample 
that was smaller than ours. Differences may be related to 
measurement tools and sample characteristics. Our sam-
ple, for instance, consisted predominantly of patients at the 
higher end of the socio-economic status spectrum. Moreo-
ver, the 21 patients with T2 assessments did not differ sig-
nificantly from healthy controls at T1 on the FI- and SSV-
tasks, which is in contrast with findings reported for the 
entire PKU sample at T1 (Huijbregts et al. 2002a, c). Even 
though the 21 patients did not differ from the 46 patients 
lost to follow-up regarding EF at T1 either, the evidence 
indicating that the T2 PKU group is relatively “well-off” or 
relatively mildly affected is more convincing than the evi-
dence showing a lack of differences between patients that 
did versus those that did not participate at T2. This should 
be considered when interpreting our study results.
An explanation for the stability or improvement of cog-
nition among PKU patients in both studies might lie in 
good or good enough treatment compliance and subsequent 
low Phe levels after childhood. The fact that the mean 
Index of Dietary Control at T2 (i.e. lifetime Phe level) was 
464 µmol/L, with a range of 276–743 µmol/L seems to sup-
port this notion. Despite the fact that Phe levels increased 
after childhood, these may still have been sufficiently low 
to allow patients to ‘close’ the gap with their healthy coun-
terparts or at least not worsen compared to them. Consider-
ing this indicator of metabolic control, further patient char-
acteristics, e.g. on education, employment, and romantic 
relationships, and the fact that this selection of patients did 
not differ from controls at T1, it cannot be ruled out either 
that our findings, and those of Nardecchia et al. (2015) and 
Weglage et  al. (2013), are positively biased and that this 
bias extends to domains beyond metabolic control.
Relatively good cognitive and psychosocial development 
of individuals with PKU over longer periods of time may 
depend upon their childhood Phe levels. Unfortunately, 
this could not be comprehensively studied by Nardecchia 
et  al. (2015) who only used Phe from the first 4  years of 
life as covariate for the negative association between life-
time Phe and executive functioning whilst critical periods 
for EF-development are known to occur beyond the age of 
four (Huijbregts et al. 2002b). This is particularly unfortu-
nate as we found evidence for the importance of childhood 
Phe levels (i.e. between 0 and 12  years) with two differ-
ent statistical approaches. First, we investigated whether 
Phe levels from different developmental stages were dif-
ferentially associated with our neurocognitive and mental 
health outcome measures. Results showed that generally 
childhood Phe as measured by IDC at T1 or Phe between 
0 and 12 years was solely or more strongly associated with 
the outcome measures at T2 (i.e. in adulthood). With two 
exceptions regarding higher-order executive functioning, 
which is known to continue development in the second 
decade of life, associations with post-childhood Phe levels 
were non-significant after controlling for childhood Phe. 
Second, we created groups of PKU patients based on Phe 
levels during childhood and thereafter, and compared out-
comes during adulthood. As a cut-off for group assignment 
we took a Phe level of 360  μmol/L, which is the recom-
mended upper target Phe level worldwide for children up 
to the age of 12 (van Spronsen et al. 2017; Vockley et al. 
2014), and, in the USA, also for the period thereafter 
(Vockley et al. 2014). As there were no patients going from 
high levels during childhood to low levels during adoles-
cence and beyond, and only three patients in the ‘low–low’ 
group, we compared two groups: the ‘low–high’ group 
(Phe <360 μmol/L until age 12 and ≥360 μmol/L from age 
13) and the ‘high–high’ group (Phe ≥360 μmol/L through-
out life). The ‘low–high’ group performed better on a num-
ber of tasks than the ‘high–high’ group, specifically with 
respect to cognitive flexibility and executive motor control, 
and also had better mental health outcomes as adults. These 
findings suggest that those patients who had low Phe in 
childhood had better outcome in adulthood than those who 
already had high Phe in their first 12 years of life.
In our study, adult mental health problems were also 
exclusively or most strongly related to elevated Phe in 
childhood. Phe between 0 and 12 years was related to 
Depressive, Somatic, Attention Deficit/Hyperactivity, 
Antisocial Personality problems, and the overall internal-
izing, externalizing and total problem scale. Associations 
between mental health problems and later Phe indices were 
no longer significant after controlling for childhood Phe. 
Brumm et al. (2010) demonstrated a relationship between 
severity of behavioural symptoms and timing and degree 
of exposure to Phe. They concluded that children with high 
Phe in earlier years were more likely to be affected and had 
more severe mental health problems. Our results are con-
sistent with their finding.
It may be considered a limitation of this study that many 
statistical tests have been carried out. After correction for 
multiple testing by using adjusted p values many significant 
results were lost. However, a pattern of results remained 
evident indicating a larger influence of childhood Phe levels 
(Phe 0–12 years, IDC1, Phe low–high vs. Phe high–high) 
compared to Phe levels later in life. Also, there are a num-
ber of arguments supporting the use of multiple statisti-
cal tests. Generally, two broad sets of analyses have been 
used: correlations between indices of metabolic control and 
outcome measures, and group-based analyses involving 
495Behav Genet (2017) 47:486–497 
1 3
comparisons between PKU patients with Phe levels below 
the recommended upper target limit as a child (0–12 years, 
below 360  µmol/L) and higher levels thereafter and PKU 
patients with Phe levels higher than 360 µmol/L through-
out life. Although the correlations were corrected for child-
hood Phe levels, which already made results indicative of 
the relative influence of Phe during different stages of life, 
the added value of the group-based analyses is that they 
relate possible differential influences of Phe during differ-
ent stages of life to treatment guidelines (i.e. the upper tar-
get Phe level of 360 µmol/L). The different IDCs that were 
included in the correlational analyses were often relatively 
strongly related, but it was still considered important to 
investigate not only IDC until T1 and until T2 but also to 
distinguish Phe levels between 0 and 12, 13 and 17 years 
and for 18 years and older because these periods are dis-
tinguished in treatment guidelines as well. Furthermore, 
results showed a potential influence of change in Phe lev-
els between childhood and thereafter that could not be cap-
tured by analyses using absolute Phe levels. Thus, it may be 
concluded that results of different tests were complemen-
tary. Another, related limitation of the present study is that 
strong evidence for further specificity in the strengths and 
weaknesses profile of PKU patients cannot be provided. 
For this, we would have to include even more tasks (assess-
ing RT and error rate) and (informant-rated) questionnaires, 
preferably in a larger sample. In general, however, clear and 
converging evidence for the continued influence of child-
hood Phe on adult cognitive (EF-) and behavioural out-
comes was provided.
The most important limitation of our study is probably 
that our sample seemed positively biased and therefore not 
entirely representative of the “average” adult PKU patient. 
Because we missed many patients who had participated as 
a child, we also had a small sample size. This would ren-
der the outcome of further comparisons unreliable, e.g. 
between  BH4 users and non-users, or a group-based analy-
sis including the ‘low–low’ group. Whereas considering the 
rarity of PKU the sample size is still acceptable and com-
parable to other studies using a follow-up design in PKU, 
future studies should seek for ways or strategies to enhance 
more comprehensive inclusion of patients. Another concern 
may be the inclusion of different subtypes of PKU, mak-
ing this sample heterogeneous. However, this enabled us 
to examine the effect of lower Phe and this was taken into 
account when analysing the ‘low–high’ and ‘high–high’ 
groups: there was no difference in type of classification 
between the two groups. A different type of limitation lies 
in the choice of Phe levels to represent metabolic control in 
different stages of development. As noted, we used 0–12, 
13–17, ≥18 years, to differentiate between different devel-
opmental stages. However, the exact age ranges represent-
ing different developmental and possibly critical stages 
for cognitive and psychosocial development are unknown. 
Whereas we made informed choices and examined Phe lev-
els during different time windows as well (e.g. the average 
Phe level between IDC at T1 and IDC at T2, which had a 
correlation of approximately r = 0.9 with Phe 13–17 years 
and similar correlations as Phe 13–17 years with outcome 
measures), more general knowledge on developmental 
milestones or critical developmental stages for EF and 
psychosocial functioning would be very helpful in this 
respect. A final limitation lies in the possible underestima-
tion of their own mental health problems by PKU patients. 
Although it is relatively custom to use self-reports in order 
to assess mental health, a more comprehensive assessment 
(using other informants and/or expert interviews) would be 
advisable for future studies.
In summary, our study showed that executive function-
ing in PKU patients is mostly stable over time from child-
hood into young adulthood, with some improvements rela-
tive to controls observed as well. Furthermore, long-term 
effects of elevated childhood Phe on cognitive and mental 
health outcome later in life were observed, supporting the 
notion that childhood Phe should be below the recom-
mended treatment target of 360 µmol/L for better outcome 
in adulthood. Although the influence of childhood Phe lev-
els was generally the strongest, the extent of the increase 
in Phe levels after childhood and Phe levels between 13 
and 17 years of age were also related to some aspects of 
adult EF. With regard to this, we cannot entirely rule out 
the influence of later Phe levels as participants were almost 
exclusively characterized by good metabolic control from 
birth onwards and had grown up in social and socio-eco-
nomic environments that may be considered protective or 
beneficial for cognitive and psychosocial development.
Acknowledgements The authors thank all PKU patients and con-
trols for participating, and the psychology and MD students for assist-
ing in this study. In addition, we thank all physicians for their full 
cooperation, the nursing staff, and the metabolic departments of all 
collaborating hospitals.
Funding This work was supported by the Dutch PKU Research 
Foundation, NutsOhra Fund, and the Division of Metabolic Diseases 
of the Beatrix Children’s Hospital of the University Medical Center 
Groningen, The Netherlands. The sponsors were not involved in the 
study design, data collection, analysis and interpretation of data, 
writing of the report, and the decision to submit the manuscript for 
publication.
Compliance with ethical standards 
Conflict of interest R. Jahja has received honoraria as a speaker 
and consultant for Merck Serono. F. J. van Spronsen was a member 
of various Scientific Advisory Boards of Merck Serono, is a mem-
ber of Scientific Advisory Boards of Danone, APR and Biomarin and 
has received grants for research purpose of both Merck Serono (later 
Biomarin) and Nutricia. Further he has received consultation fees and 
speaker relation fees from Merck Serono, Biomarin, Nutricia and Vi-
496 Behav Genet (2017) 47:486–497
1 3
taflo. He has assisted in the design of clinical studies using products 
manufactured by Biomarin. He chairs the Scientific Advisory Board of 
the ESPKU and is the chairman of the group developing guidelines on 
PKU in Europe. L. M. J. de Sonneville declares receipt of consultation 
fees as consultant of Danone, FrieslandCampina, and Global Pharma 
Consultancy. A. M. Bosch is a member of Scientific Advisory Boards 
of Merck Serono and Danone, and was also involved in developing 
guidelines on PKU in Europe. S. C. J. Huijbregts has participated in 
strategic advisory boards and received honoraria as a consultant and/
or speaker for Merck Serono SA, Biomarin, and Nutricia. He is also 
a member of the group developing guidelines on PKU in Europe. J. 
J. van der Meere, C. E. M. Hollak, M. E. Rubio-Gozalbo, M. C. G. J. 
Brouwers, F. C. Hofstede, M. C. de Vries, M. C. H. Janssen, A. T. van 
der Ploeg, and J. G. Langendonk declare that they have no conflict of 
interest.
Ethical approval All procedures performed were in accordance with 
the ethical standards of the institutional and national research commit-
tee and with the 1964 Helsinki Declaration and its later amendments 
or comparable ethical standards.
Informed consent Informed consent was obtained from all partici-
pants for being included in the study.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Achenbach TM, Rescorla LA (2003) Manual for the ASEBA adult 
forms & profiles. University of Vermont, Research Center for 
Children, Youth and Families, Burlington
Albrecht J, Garbade SF, Burgard P (2009) Neuropsychological speed 
tests and blood phenylalanine levels in patients with phenylke-
tonuria: a meta-analysis. Neurosci Biobehav Rev 33:414–421
Anjema K, van Rijn M, Verkerk PH, Burgerhof JG, Heiner-Fokkema 
MR, van Spronsen FJ (2011) PKU: high plasma phenylalanine 
concentrations are associated with increased prevalence of mood 
swings. Mol Genet Metab 104:231–234
Antenor-Dorsey JA, Hershey T, Rutlin J, Shimony JS, McKinstry RC, 
Grange DK, Christ SE, White DA (2013) White matter integrity 
and executive abilities in individuals with phenylketonuria. Mol 
Genet Metab 109:125–131
Arnold GL, Kramer BM, Kirby RS, Plumeau PB, Blakely EM, 
Sanger Cregan LS, Davidson PW (1998) Factors affecting cog-
nitive, motor, behavioral and executive functioning in children 
with phenylketonuria. Acta Paediatr 87:565–570
Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 
376:1417–1427
Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U (2011) 
Diagnosis, classification, and genetics of phenylketonuria and 
tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 
104(Suppl):S2–S9
Brumm VL, Bilder D, Waisbren SE (2010) Psychiatric symptoms 
and disorders in phenylketonuria. Mol Genet Metab 99(Suppl 
1):S59–S63
Cappelletti S, Cotugno G, Goffredo BM, Nicolo R, Bernabei SM, 
Caviglia S, Di Ciommo V (2013) Cognitive findings and 
behavior in children and adolescents with phenylketonuria. J 
Dev Behav Pediatr 34:392–398
CBS (2016a) StatLine. https://www.cbs.nl/nl-nl/cijfers#filter=all 
(2016)
CBS (2016b) StatLine: Arbeidsdeelname; regionale indeling 
2015. CBS, Den Haag/Heerlen. http://statline.cbs.nl/Stat-
web/publication/?VW=T&DM=SLNL&PA=83360NED&
D1=0,15&D2=0,13&D3=0,101-493&D4=l&HD=160518-
1003&HDR=G3,G1,T&STB=G2 (2016)
Christ SE, Huijbregts SC, de Sonneville LM, White DA (2010) 
Executive function in early-treated phenylketonuria: pro-
file and underlying mechanisms. Mol Genet Metab 99(Suppl 
1):S22–S32
De Sonneville L (2014) Handboek ANT. Amsterdamse Neuropsy-
chologische Taken. Boom Test Uitgevers, Amsterdam
DeRoche K, Welsh M (2008) Twenty-five years of research on neuro-
cognitive outcomes in early-treated phenylketonuria: intelligence 
and executive function. Dev Neuropsychol 33:474–504
Dyer CA (1999) Pathophysiology of phenylketonuria. Mental Retard 
Dev Disabil Res Rev 5:104–112
Huijbregts S, de Sonneville L, Licht R, Sergeant J, van Spronsen F 
(2002a) Inhibition of prepotent responding and attentional flex-
ibility in treated phenylketonuria. Dev Neuropsychol 22:481–499
Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk 
PH, Sergeant JA (2002b) Sustained attention and inhibition of 
cognitive interference in treated phenylketonuria: associations 
with concurrent and lifetime phenylalanine concentrations. Neu-
ropsychologia 40:7–15
Huijbregts SC, de Sonneville LM, van Spronsen FJ, Licht R, Sergeant 
JA (2002c) The neuropsychological profile of early and continu-
ously treated phenylketonuria: orienting, vigilance, and mainte-
nance versus manipulation-functions of working memory. Neu-
rosci Biobehav Rev 26:697–712
Huijbregts SC, De Sonneville LM, Van Spronsen FJ, Berends IE, 
Licht R, Verkerk PH, Sergeant JA (2003) Motor function 
under lower and higher controlled processing demands in early 
and continuously treated phenylketonuria. Neuropsychology 
17:369–379
Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, Bosch 
AM, Hollak CE, Rubio-Gozalbo ME, Brouwers MC, Hofstede 
FC, de Vries MC, Janssen MC, van der Ploeg AT, Langendonk 
JG, van Spronsen FJ (2013) Mental health and social functioning 
in early treated phenylketonuria: the PKU-COBESO study. Mol 
Genet Metab 110(Suppl):S57–S61
Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, van 
Spronsen FJ (2014) Neurocognitive evidence for revision of 
treatment targets and guidelines for phenylketonuria. J Pediatr 
164(895–899):e2
Jahja R, van Spronsen FJ, de Sonneville LM, van der Meere JJ, Bosch 
AM, Hollak CE, Rubio-Gozalbo ME, Brouwers MC, Hofstede 
FC, de Vries MC, Janssen MC, van der Ploeg AT, Langendonk 
JG, Huijbregts SC (2016) Social-cognitive functioning and social 
skills in patients with early treated phenylketonuria: a PKU-
COBESO study. J Inherit Metab Dis 39:355–62
Moyle JJ, Fox AM, Arthur M, Bynevelt M, Burnett JR (2007) Meta-
analysis of neuropsychological symptoms of adolescents and 
adults with PKU. Neuropsychol Rev 17:91–101
Nardecchia F, Manti F, Chiarotti F, Carducci C, Carducci C, Leuzzi 
V (2015) Neurocognitive and neuroimaging outcome of early 
treated young adult PKU patients: A longitudinal study. Mol 
Genet Metab 115:84–90
Roth RM, Isquith PK, Gioia GA (2005) BRIEF-A. Behavior rating 
inventory of executive function-adult version. Psychological 
Assessment Resources, Inc, Lutz
497Behav Genet (2017) 47:486–497 
1 3
Smith I, Knowles J (2000) Behaviour in early treated phenylketonuria: 
a systematic review. Eur J Pediatr 159(Suppl 2):S89–S93
van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de 
Blaauw P, Kema IP, Heiner-Fokkema MR, van Anholt RD, van 
der Zee EA, van Spronsen FJ (2015) Large neutral amino acid 
supplementation exerts its effect through three synergistic mech-
anisms: proof of principle in phenylketonuria mice. PLoS ONE 
10:e0143833
van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MH, de 
Blaauw P, Pascucci T, Puglisi-Allegra S, Kema IP, Heiner-Fok-
kema MR, van der Zee EA, van Spronsen FJ (2016) Therapeutic 
brain modulation with targeted large neutral amino acid supple-
ments in the Pah-enu2 phenylketonuria mouse model. Am J Clin 
Nutr 104:1292–1300
van Spronsen F, van Wegberg A, Ahring K, Bélanger-Quintana A, 
Blau N, Bosch A, Burlina A, Campistol J, Feillet F, Giżewska 
M, Huijbregts S, Kearney S, Leuzzi V, Maillot F, Muntau A, 
Trefz F, van Rijn M, Walter J, MacDonald A (2017) Key Euro-
pean guidelines for the diagnosis and management of patients 
with phenylketonuria. Lancet Diabetes Endocrinol. doi:10.1016/
S2213-8587(16)30320-5
Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, 
Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA, 
American College of Medical Genetics and Genomics Therapeu-
tics Committee (2014) Phenylalanine hydroxylase deficiency: 
diagnosis and management guideline. Genet Med 16:188–200
Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, 
Levy H (2007) Phenylalanine blood levels and clinical outcomes 
in phenylketonuria: a systematic literature review and meta-anal-
ysis. Mol Genet Metab 92:63–70
Walter JH, White FJ (2004) Blood phenylalanine control in adoles-
cents with phenylketonuria. Int J Adolesc Med Health 16:41–45
Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, 
Francis DE, Shortland GJ, Schmidt M, Vail A (2002) How prac-
tical are recommendations for dietary control in phenylketonu-
ria? Lancet 360:55–57
Weglage J, Grenzebach M, Pietsch M, Feldmann R, Linnenbank R, 
Denecke J, Koch HG (2000) Behavioural and emotional prob-
lems in early-treated adolescents with phenylketonuria in com-
parison with diabetic patients and healthy controls. J Inherit 
Metab Dis 23:487–496
Weglage J, Fromm J, van Teeffelen-Heithoff A, Moller HE, Koletzko 
B, Marquardt T, Rutsch F, Feldmann R (2013) Neurocognitive 
functioning in adults with phenylketonuria: results of a long term 
study. Mol Genet Metab 110(Suppl):S44–S48
